Dual Monoclonal Antibody Therapy for a Severe Asthma Patient
Author:
Publisher
Frontiers Media SA
Subject
Pharmacology (medical),Pharmacology
Reference23 articles.
1. Combination omalizumab and mepolizumab therapy for refractory allergic bronchopulmonary aspergillosis;Altman;J. Allergy Clin. Immunol. Pract.,2017
2. Guiding principles for use of newer biologics and bronchial thermoplasty for patients with severe asthma;Blaiss;Ann. Allergy Asthma Immunol.,2017
3. Care pathways for the selection of a biologic in severe asthma;Bousquet;Eur. Respir. J.,2017
4. The eXpeRience registry: the ‘real-world’ effectiveness of omalizumab in allergic asthma;Braunstahl;Respir. Med.,2013
5. Are peripheral blood eosinophil counts a guideline for omalizumab treatment? STELLAIR says no;Busse;Eur. Respir. J.,2018
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarmin pathways;Immunological Reviews;2024-08-19
2. Combination of monoclonal antibodies targeting type 2 inflammation for severe asthma and eosinophilic granulomatosis with polyangiitis;Autoimmunity Reviews;2024-03
3. Dual biologics for severe asthma and atopic dermatitis: Synopsis of two cases and literature review;Respirology Case Reports;2023-12-06
4. Evaluation of antibody drug delivery efficiency via nebulizer in various airway models and breathing patterns;BMC Pharmacology and Toxicology;2023-12-01
5. Combination of Biological Therapy in Severe Asthma: Where We Are?;Journal of Personalized Medicine;2023-11-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3